drugset / Trial / NCT01153919
Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
RandomizedCrossoverDouble-blindTreatment
Summary
RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.
Timeline
- Start
- 2010-06-30
- Primary completion
- 2014-07-14
- Completion
- 2018-07-14
Outcome
Outcome not reported
Stopped: “Approval of several new agents for the treatment of HCV infection would mitigate the future need for interferon HCV treatment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Romiplostim | Peptide | — | Subcutaneous |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | Ribavirin | Small molecule | — | Oral |